Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when ...

Vepdegestrant significantly improved outcomes for certain patients with ER-positive, HER2-negative advanced breast cancer ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Patients were randomly assigned in a 1:1 ratio to receive vepdegestrant at a dose of 200 mg orally once every day of each 28-day cycle or fulvestrant at a dose of 500 mg, administered ...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...